Adalimumab

Adalimumab Reactions 1680, p16 - 2 Dec 2017 Subacute thyroiditis and thyrotoxicosis: case report A 50-year-old woman developed subacute thyroiditis (SAT) and thyrotoxicosis during treatment with adalimumab. The woman, who was diagnosed with psoriatic arthritis in 2013, was on SC adalimumab 40mg every other week. She was admitted due to complaints of fever from two weeks and pharyngeal pain. She received treatment with amoxicillin without effect. Rapidly, a painful thyroid goiter with clinical signs of thyrotoxicosis appeared. Blood tests showed systemic inflammation with a c-reactive protein of 115 mg/L) and hyperthyroidism with undetectable circulating thyroid stimulating hormone and increased T4 and T3 levels. Anti- thyroid antibodies were negative, except for anti-thyroglobulin antibodies of 351 UI/mL. Ultrasonography of thyroid showed an increased hypervascularised pattern. Iodine 123 scintiggraphy revealed asymmetric fixation capture at the lower normal limit. She was diagnosed with SAT was made [duration of treatment to reaction onset not stated]. The woman was treated with aspirin [acetylsalicylic acid] with no efficacy. Then, she was treated with unspecified corticosteroids for two weeks and progressive decay was administered. Her symptoms improved significantly and progressive hypothyroidism appeared. Adalimumab was not restarted. Author comment: "We report here a subacute thyroiditis in a [psoriatic arthritis] patient treated by adalimumab. The physician might be aware of this unusual complication of [TNF inhibitor]." Senlis M, et al. Subacute thyroiditis in psoriatic arthritis treated by adalimumab. Joint Bone Spine 84: 745-746, No. 6, Dec 2017. Available from: URL: http:// doi.org/10.1016/j.jbspin.2016.09.015 - France 803285194 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Adalimumab

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/adalimumab-xHZvm0xGMW
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38947-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial